Civitas Therapeutics, Inc
Civitas Therapeutics, Inc., located in Chelsea, MA, has undergone significant changes with the acquisition of its products, including AMP YRA, Adalfampridine, INBRIJA, levodopa inhalation powder, and ARCUS technology, by Merz Therapeutics. These products will continue to be available to customers through Merz Therapeutics.
As of August 21, 2024, Acorda Therapeutics Inc. exited Chapter 11 bankruptcy, with all remaining assets now held by the Acorda Therapeutics Liquidation Trust. For further details regarding the Chapter 11 Plan of Reorganization or the Liquidation Trust, additional resources are available online.
Generated from the website
Also at this address
You might also like
Partial Data by Infogroup (c) 2025. All rights reserved.
Partial Data by Foursquare.
